Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapyThis potentially enables treatment for patients...
– BBP-398, an investigational SHP2 inhibitor, is a potentially best-in-class therapy for use in combination approaches, which is shown by...
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed...
WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage...
– Initial first-in-human clinical data for IL-2 INDUKINE WTX-124 monotherapy expected in 4Q 2023 from Phase 1/1b clinical trial in...
HAMILTON, BERMUDA, March 22, 2023 (GLOBE NEWSWIRE) -- Preprint of results from animal study shows restriction of tumor growth in...
SOUTH SAN FRANCISCO, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that the Compensation Committee of...
Chief Science Officer describes compelling preclinical data supporting continued development of PLACCINE as a differentiated, next-generation vaccine modality LAWRENCEVILLE, N.J.,...
NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and...
Company Unveils EVOLVE-105 Program, A Best-in-Class CD20xCD3 Multispecific Antibody Designed to Concurrently Drive CD2 Costimulation to Improve the Treatment of...
The UCLA research team, which includes Dr. Steven Jonas, Dr. Christopher Seet, Dr. Satiro De Oliveira and Dr. Christopher Denny,...
NEW YORK, March 17, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company...
Enrollment Underway in Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors with First Patient Dosed In March...
NORCROSS, Ga., March 16, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3,...
FLORHAM PARK, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a...
FORT LEE, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating...
- Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas underway - - Ended 2022 with cash,...
Experienced Life Science Operating Leader Joins Board as Company Enters New PhaseSOUTH SAN FRANCISCO, Calif., March 15, 2023 (GLOBE NEWSWIRE)...
SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools...
-Pilot study in Ewing's Sarcoma supports the therapeutic potential of Vigil in multiple solid tumor types- -Circulating tumor DNA levels,...